Clinical Trial Update: EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety [Phase 2]

View source ↗

Summary

Phase 2 EXACT study evaluating Exaluren for Alport syndrome (X-linked and autosomal recessive) is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alport Syndrome

Drugs mentioned

• Exaluren (Exaluren)

Snippet

Sponsor: Eloxx Pharmaceuticals, Inc. | Conditions: Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive | Phase 2 | Status: NOT_YET_RECRUITING